Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?

Movement Disorders

Volumn 26, Issue 7, 2011, Pages 1187-1193

  Clarke, Carl E ^a,b   Patel, Smitaa ^b   Ives, Natalie ^b   Rick, Caroline ^b   Wheatley, Keith ^c   Gray, Richard ^b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Health economics; Parkinson's disease; Quality of life; Treatment

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG DOSE COMPARISON; FUNCTIONAL DISEASE; HUMAN; META ANALYSIS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THERAPY DELAY;

ANTIPARKINSON AGENTS; DISABILITY EVALUATION; EARLY DIAGNOSIS; HUMANS; PARKINSON DISEASE; WATCHFUL WAITING;

EID: 79959344258     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23519     Document Type: Article

References (33)

1. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005; 76: 343-348.
2. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007; 22: 938-945.
3. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005; 62: 378-382.
4. Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.
5. Lang AE. The progression of Parkinson disease: a hypothesis. Neurology 2007; 68: 948-952.
6. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006; 59: 559-562.
7. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002; 51: 604-612.
8. Parkinson Study Group. A controlled, randomised, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566.
9. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
10. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
11. Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I. Disease progression and pharmacodynamics in Parkinson disease-evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006; 33: 281-311.
12. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009; 24: 564-573.
13. Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm Res 2007; 24: 791-802.
14. Whone A, Watts R, Stoessl A, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
15. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661.
16. Albin R. Initial agonist treatment of Parkinson's disease. Neurology 2003; 60: 390-394.
17. Ahlskog JE. Slowing Parkinson's disease progression. Neurology 2003; 60: 381-389.
18. Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002; 360: 1767-1769.
19. Wooten G. Agonists versus levodopa in Parkinson's disease. Neurology 2003; 60: 360-363.
20. Schapira A, Albrecht S, Barone P, et al. Immediate versus delayed-start pramipexole in early Parkinson's disease: the PROUD study. In: 18th World Federation of Neurology World Congress on Parkinson's Disease and Related Movement Disorders. Miami Beach; 2009.
21. Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007; 78: 465-469.
22. Asimakopoulos P, Caslake R, Harris CE, Gordon JC, Taylor KS, Counsell C. Changes in quality of life in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 716-718.
23. Biglan KM, Schwid S, Eberly S, et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006; 21: 616-623.
24. Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 2008; 23: 784-789.
25. Ploeger BA, Holford NH. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm Stat 2009; 8: 225-238.
26. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006; 21: 1200-1207.
27. Rascol O. Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need. Mov Disord 2006; 21: 1059-1061.
28. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010; 67: 64-70.
29. Movement Disorders Society Task Force. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003; 18: 738-750.
30. Department of Health. Available at:, 2009.
31. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-183.
32. Lees AJ, Parkinson's Disease Research Group of the United Kingdom. Comparison of the therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311: 1602-1607.
33. Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004; 329: 593-560